Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Stock Information for Adial Pharmaceuticals Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adial Pharmaceuticals Inc

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.